ATTENTION: Please enable Javascript in your browser for full site functionality.
Skip to navigation Skip to main content Skip to footer

Ticker Update

Updates

SUB-TYPE:

14.06.2021

Change to Emergency Out of Hours Contact

As part of our ongoing commitment to improve the service we provide, we are making some changes to how customers request an emergency order, which will make the process more efficient and user friendly.

 

·         In the event of an emergency (i.e., urgent CD lines being required) when the service centre is open or when the service centre is closed, please call Customer Service on 0330 100 0448.

 

·        Outside of normal opening hours, when you enter your account number you will hear a message advising you of your supplying Service Centre which you will need to make a note of. You will then be directed to the out of hours security company who will handle your call and direct it to the appropriate service centre.

 

·         The previous numbers will no longer be in use, so please ensure you update your records with the number above to ensure there is no delay with your request.

 

 

Please note -  All emergency call outs will incur a £100 charge, plus courier charges.

SUB-TYPE: COMPANY-LED RECALL

09.06.2021

COMPANY-LED DRUG ALERT – Alliance do not stock

The importer and distributor of the below products (Eaststone Limited) has informed us of reports that two affected batches may be contaminated with mould. Therefore, these batches are being recalled as a precautionary measure. This recall is being issued as a company-led recall due to the limited number of packs distributed, and Eaststone Limited have full traceability of the onward distribution by their customers.

 

Please can you ensure that your stores quarantine the product listed below

Pip code

Product

Supplier

Affected Batches

Alliance do not stock

Noidecs T20/C4 (THC 20%; CBD 4%) Sativa Cannabis Flower

Eaststone Limited

14NS2021002

Alliance do not stock

Noidecs T20/C4 (THC 20%; CBD 4%) Indica Cannabis Flower

Eaststone Limited

14NI2021002

Alliance do not stock these products and therefore we are not accepting stock returns.

 

Company Contact for medical information enquiries

For medical information enquiries, please contact: Omair Sattar

Email: omair.sattar@eaststone.co.uk

Tel: 01942 841 704

 

Company Contact for stock enquiries

For stock information enquiries, please contact: Omair Sattar

Email: omair.sattar@eaststone.co.uk

Tel: 01942 841 704

SUB-TYPE:

02.06.2021

AmerisourceBergen completes acquisition of Alliance Healthcare businesses

Acquisition Advances Role as a Key Pillar of Pharmaceutical Innovation and Access Adjusted Diluted EPS Guidance Range Raised to $8.90 to $9.10 for Fiscal 2021

 

CONSHOHOCKEN, PA, JUNE 2, 2021 — AmerisourceBergen Corporation (NYSE: ABC) today announced the completion of its acquisition of the majority of Walgreens Boots Alliance’s Alliance Healthcare businesses for $6.275 billion in cash, subject to a customary working capital and net debt adjustment, and 2 million shares of AmerisourceBergen common stock.

 

“We are excited to complete the acquisition and extend a warm welcome to the talented team at Alliance Healthcare,” said Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen. “The acquisition of Alliance Healthcare expands our reach and solutions in pharmaceutical distribution and adds to AmerisourceBergen’s breadth and depth of global manufacturer services. With Alliance Healthcare, we will advance our ability to provide innovative and global healthcare solutions and further our purpose of being united in our responsibility to create healthier futures.”

 

“This transaction provides great benefit for both companies and is a logical step following the continued success of our long-term strategic relationship,” said Ornella Barra, Chief Operating Officer, International, Walgreens Boots Alliance, Inc. “The Alliance Healthcare teams are joining a global pharmaceutical distribution leader and trusted partner in AmerisourceBergen, and we look forward to continuing to work together as strategic partners.

 

AmerisourceBergen and Walgreens Boots Alliance will also execute on the expansion and extension of commercial agreements in order to drive incremental growth and synergies.

 

Fiscal Year 2021 Expectations

 

The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available or cannot be reasonably estimated.

 

Fiscal Year 2021 Expectations on an Adjusted (non-GAAP) Basis

 

AmerisourceBergen has updated its fiscal year 2021 financial guidance to reflect the expected contribution from the closing of the Alliance Healthcare acquisition and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the Company delivered at closing of the transaction. The Company now expects:

 

• Revenue of at least $210 billion, up from revenue growth in the high-single digit percent range; and

• Adjusted diluted earnings per share (EPS) to be in the range of $8.90 to $9.10, raised from the previous range of $8.45 to $8.60.

 

 

Additional expectations now include:

 

• Weighted average shares of at least 208 million, raised from the previous expectation of between 207 million and 208 million for the fiscal year.

 

The Company continues to have strong performance across its businesses and expects to update the rest of its previously announced fiscal 2021 financial guidance when it reports results for the third quarter of fiscal 2021. Alliance Healthcare’s results will be reported in Other for the remainder of fiscal year 2021.

 

Please refer to the Supplemental Information Regarding Non-GAAP Financial Measures below.

 

About AmerisourceBergen

 

AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 41,000 global team members power our purpose: We are united in our 3 responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at investor.amerisourcebergen.com.

 

Supplemental Information Regarding Non-GAAP Financial Measures

 

To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses adjusted diluted EPS. Adjusted diluted EPS should be viewed in addition to, and not in lieu of, financial measures calculated in accordance with GAAP. Adjusted diluted EPS may vary from, and may not be comparable to, similarly titled measures by other companies.

 

Adjusted diluted EPS is presented because management uses this non-GAAP financial measure to evaluate the Company’s operating performance, to perform financial planning, and to determine incentive compensation. Therefore, the Company believes that the presentation of this non-GAAP financial measure provides useful supplementary information to, and facilitates additional analysis by, investors.

 

The non-GAAP fiscal year 2021 guidance for adjusted diluted EPS excludes significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-recurring or non-cash in nature. The Company does not provide forward looking guidance on a GAAP basis for such metric because certain financial information, the probable significance of which cannot be determined, is not available and cannot be reasonably estimated.

 

For fiscal year 2021, adjusted diluted EPS excludes the per share impact of certain adjustments including gain from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization; and employee severance, litigation, and other; in each case net of the tax effect calculated using the applicable effective tax rate for those items. Management believes that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.

 

AmerisourceBergen's Cautionary Note Regarding Forward-Looking Statements

 

Certain of the statements contained in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Such forward-looking statements may include, without limitation, statements about the Alliance Healthcare acquisition, the benefits of the Alliance Healthcare acquisition, future opportunities for AmerisourceBergen and any other statements regarding AmerisourceBergen’s future operations, financial or operating results, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competitions, and other expectations and targets for future periods. Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "intend," "plan," "continue," "sustain," "synergy," "on track," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," variations of such words, and similar expressions are intended to identify such forward looking statements.

 

These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove 4 incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or costly than expected; the Company’s or Alliance Healthcare’s failure to achieve expected or targeted future financial and operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the respective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of businesses, including the Alliance Healthcare businesses and related strategic transactions, that do not perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and the Company, including with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the loss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company’s operations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational 5 factors affecting the Company's business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forwardlooking statements are set forth (i) in Item 1A (Risk Factors), in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.

 

 

 

SUB-TYPE: CLASS 3 RECALL

CLASS 3 RECALL - CARBIMAZOLE TAB 10MG & 15MG

Advanz Pharma is recalling the below batches of Carbimazole tablets as a precautionary measure, due to an out of specification observation for tablet appearance of samples during routine stability testing. Based on the investigation performed, the observed defect was related to oxidation of the excipient red iron oxide on the surface of the tablets, due to a lack of proper mixing during the manufacturing process. There is no safety or efficacy issues as a result of this observation.

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-intrapharm-laboratories-ltd-kolanticon-gel-500ml-el-21-a-slash-01?utm_medium=email&utm_campaign=govuk-notifications&utm_source=1c3cadd1-c259-4e77-b3e8-c13faf584fe2&utm_content=immediately  

Pip code

Product description

Supplier

Batch Numbers

8127730

CARBIMAZOLE TAB 10MG

ADVANZ PHARMA

120963

121025

1233931

CARBIMAZOLE TAB 10MG

ADVANZ PHARMA

120963

121025

8127938

CARBIMAZOLE TAB 15MG

ADVANZ PHARMA

120967

121028

Further Information

 

For more information or medical information queries please contact +44 (0) 8700 70 30 33 , or email medicalinformation@advanzpharma.com.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies

 

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: COMPANY-LED RECALL

Company Led - DRUG ALERT - LYSAKARE 25 G / 25 G SOLUTION FOR INFUSION

Advanced Accelerator Applications Ltd is recalling the below batch of LysaKare 25 g / 25 g solution for infusion (PLGB 35145/0005) as it was identified during the inspection process by the manufacturer that a small number of bags were observed to be leaking..”

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/company-led-medicines-recall-lysakare-25-g-slash-25-g-solution-for-infusion-plgb-35145-slash-0005?utm_medium=email&utm_campaign=govuk-notifications&utm_source=125027c5-2625-4ae7-a249-7c9dc4b72260&utm_content=immediately   

Pip code

Product description

Supplier

Batch numbers

Alliance do not stock

LYSAKARE 25 G / 25 G SOLUTION FOR INFUSION

ADVANCED ACCELERATOR APPLICATIONS (UK & IRELAND) LTD

210155

 

Alliance do not stock this product and therefore we are not accepting stock returns.

 

Company contact for medical information enquiries

For medical information enquiries, please contact: Advanced Accelerator Applications (UK & Ireland) Ltd infomed@adacap.com.

 

Company contact for stock enquiries

For stock information enquiries contact Advanced Accelerator Applications (UK & Ireland) Ltd by emailing: customersvc.aaauk@novartis.com, tel. +44(0)20 72585200

 

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: FIELD SAFETY NOTICE

COMPANY LED FIELD SAFETY NOTICE- ARTELAC REBALANCE 10ML

The product recall for the affected batch is due to the incorrect shipment of products intended for the Belgian market to the UK/Ireland markets. As a result part of the shipments for batch 520 of Artelac Rebalance contain products with German/French/Dutch labelling. The labelling and Instructions for Use should be understood by all users in their country official language. Therefore German/French/Dutch labelled products must not be distributed in UK or Ireland

MHRA drug alert link: N/A   

Pip code

Product description

Supplier

Batch numbers

3620549

ARTELAC REBALANCE 10ML

BAUSCH & LOMB

LOT 520

 

If you have any questions, please contact Bausch + Lomb Customer Service.

Email: Pharma_CS@bausch.com

Phone: 0845 602 2350

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

 

If you have any questions, then please contact your local Service Centre Customer Services team.

SUB-TYPE: CLASS 2 RECALL

CLASS 2 RECALL - BRICANYL AMP 0.5MG/1ML

AstraZeneca UK Limited is recalling the below batch of Bricanyl 0.5mg/ml solution for injection or infusion as a precautionary measure due to out of specification results for a routinely tested known impurity during stability testing

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-astrazeneca-uk-limited-bricanyl-injection-0-dot-5-mg-slash-ml-solution-for-injection-or-infusion-pl-17901-slash-0112-el-21-a-slash-12?utm_medium=email&utm_campaign=govuk-notifications&utm_source=42605459-ef94-4b7e-bb39-33e83dbc6d74&utm_content=immediately   

Pip code

Product description

Supplier

Batch Numbers

0035188

BRICANYL AMP 0.5MG/1ML

ASTRAZENECA

F1029-1

 

Please note that Alliance Healthcare do not stock and we are therefore not accepting stock returns.

 

For more information or medical information queries please contact

 

Tel: +44 (0) 0800 783 0033

 

Email: medical.informationuk@astrazeneca.com

 

For supply queries, please contact

 

Tel: +44 (0) 800 783 0033 (option 1)

 

Email: supply.chain@astrazeneca.com.

SUB-TYPE: FIELD SAFETY NOTICE

FIELD SAFETY NOTICE - HISTOACRYL ADH TISSUE BLU

: B. Braun have detected new additional batches where the adhesive could not polymerize completely after its application. The tested products did not show the normal curing behaviour, providing lower adhesive forces than expected.

MHRA drug alert link: N/A

Pip code

Product description

Supplier

Batch numbers

0416024

HISTOACRYL ADH TISSUE BLU

BRAUN B MEDICAL

220395N2

220401N1

220403N1

220414N1

220411N2

220444N2

220414N2

220444N1

220444N3

220445N3

220451N1

220445N1

220481N1

220481N2

220481N3

220484N1

220484N3

 

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

 

If you have any questions, then please contact your local Service Centre Customer Services team

SUB-TYPE:

12.05.2021

Late May 2021 Bank Holiday Opening Hours now available

To help keep our customers informed of changes to our service, we have published our Late May 2021 Bank Holiday opening hours.

Click here

SUB-TYPE:

10.05.2021

Alliance Healthcare Supports Team Members’ Mental Wellbeing by Launching Mental Health First Aiders

 

To mark Mental Health Awareness Week, Alliance Healthcare has introduced its first cohort of employee mental health first aiders.

 

The Mental Health First Aid (MHFA) England accredited training will help to identify people who may require help and signpost them to appropriate support services.

 

The first group of 24 took part in a series of virtual training programmes, which covered the issues that impact and relate to people’s mental health. These included active listening, starting a conversation about poor mental health, offering reassurance and sign posting to appropriate professional help.

 

Vicki Wilder, Senior HR Business Partner, who is leading on the training programme said: “We have a duty of care to support our workforce and we are committed to providing appropriate help for poor mental health, it’s equally as important as physical health. We also recognise that the pandemic has taken its toll on people, but with the introduction of mental health first aiders colleagues will have an additional avenue to be able to reach out for support.”
 

Alliance Healthcare will continue its mental health first aider training and by the end of 2021 every employee will have access to a trained mental health first aider.

 

Approximately one in four people in the UK will experience a mental health problem of some kind each year[1].

 

One in six people will also report experiencing a common mental health problem (like anxiety and depression) in any given week in England[2].

 

[1] Source: Mind, June 2020

[2] Source: Mind, June 2020

 

Vicki Wilder, Senior HR Business Partner
Vicki Wilder, Senior HR Business Partner